In particular, the exon 19-deletion mutation of EGFR is recurrently observed in non-small cell lung cancer (NSCLC) patients, which accounts for nearly 50% of all EGFR abnormalities [10, 12, 13]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.